Skip to main content
Signal8

Dogwood Therapeutics, Inc. (DWTX) Form 10-Q — Nov 6, 2026

$DWTXForm 10-QFiled Nov 6, 2026, 9:18 AM ET0001104659-26-123635Original filing

Dogwood Therapeutics filed its Q3 2026 10-Q with a substantial-doubt going-concern disclosure: cash of $4.9 million plus $5 million raised in the October Sealbond private placement funds operations only through March 2027. The company posted a Q3 net loss of $4.9 million and a nine-month net loss of $21.4 million, including a $9.2 million non-cash IPR&D impairment on the Halneuron CINP asset earlier in 2026; goodwill and the remaining IPR&D asset remain at risk of further impairment.

Key figures

Total Debt
0
Total Assets
75608219
Cash Position
4948266
Shares Outstanding
38227913
Runway through
March 2027
Accumulated deficit
129475481
Sealbond offering shares
4098360
Licensing revenue q3 2026
100000
Net loss nine months 2025
30476921
Net loss nine months 2026
21399165
Halneuron phase2b patients
239
Net loss three months 2026
4882942
Iprd impairment nine months 2026
9190897
Sealbond offering gross proceeds
5000000
Sealbond offering price per share
1.22
Operating cash outflow nine months 2026
12834643

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.